drugset / Trial / NCT07364214

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

NCT07364214

Phase 1 Completed 8 enrolled Arcus Biosciences, Inc.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to investigate the routes of elimination and overall mass balance of 100 mg quemliclustat containing 75 μCi \[14C\] following a single IV infusion of \[14C\]-quemliclustat in healthy adult male participants, and to quantify total radioactivity (TRA) in plasma, whole blood, urine, and feces.

Timeline

Start
2026-02-03
Primary completion
2026-04-06
Completion
2026-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Quemliclustat Small molecule 100 mg Intravenous

Indications

No indication recorded.